GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Cyclically Adjusted Book per Share

BriaCell Therapeutics (TSX:BCT) Cyclically Adjusted Book per Share : C$6.79 (As of Jan. 2024)


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BriaCell Therapeutics's adjusted book value per share for the three months ended in Jan. 2024 was C$-0.678. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$6.79 for the trailing ten years ended in Jan. 2024.

During the past 12 months, BriaCell Therapeutics's average Cyclically Adjusted Book Growth Rate was -74.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -37.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BriaCell Therapeutics was -5.80% per year. The lowest was -37.10% per year. And the median was -11.60% per year.

As of today (2024-06-08), BriaCell Therapeutics's current stock price is C$1.90. BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2024 was C$6.79. BriaCell Therapeutics's Cyclically Adjusted PB Ratio of today is 0.28.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BriaCell Therapeutics was 0.66. The lowest was 0.00. And the median was 0.00.


BriaCell Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cyclically Adjusted Book per Share Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.38 68.32 55.76 37.17 16.97

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.89 22.02 16.97 11.88 6.79

Competitive Comparison of BriaCell Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.



BriaCell Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Jan. 2024 was:

Adj_Book= Book Value per Share /CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.678/125.0724*125.0724
=-0.678

Current CPI (Jan. 2024) = 125.0724.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201404 150.551 98.920 190.353
201407 -0.017 99.315 -0.021
201410 11.591 99.473 14.574
201501 7.126 98.209 9.075
201504 6.752 99.710 8.469
201507 5.279 100.579 6.565
201510 4.040 100.500 5.028
201601 2.627 100.184 3.280
201604 4.785 101.370 5.904
201607 3.375 101.844 4.145
201610 6.411 102.002 7.861
201701 5.383 102.318 6.580
201704 6.005 103.029 7.290
201707 2.697 103.029 3.274
201710 3.319 103.424 4.014
201801 1.558 104.056 1.873
201804 5.686 105.320 6.752
201807 2.343 106.110 2.762
201810 0.876 105.952 1.034
201901 -1.475 105.557 -1.748
201904 1.314 107.453 1.529
201907 -1.380 108.243 -1.595
201910 -1.490 107.927 -1.727
202001 -4.101 108.085 -4.746
202004 -5.363 107.216 -6.256
202007 -6.725 108.401 -7.759
202010 -5.768 108.638 -6.641
202101 -5.985 109.192 -6.855
202104 2.291 110.851 2.585
202107 2.271 112.431 2.526
202110 4.481 113.695 4.929
202201 3.776 114.801 4.114
202204 3.728 118.357 3.940
202207 0.861 120.964 0.890
202210 0.912 121.517 0.939
202301 -0.111 121.596 -0.114
202304 -0.512 123.571 -0.518
202307 -0.312 124.914 -0.312
202310 0.233 125.310 0.233
202401 -0.678 125.072 -0.678

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


BriaCell Therapeutics  (TSX:BCT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BriaCell Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.90/6.79
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BriaCell Therapeutics was 0.66. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BriaCell Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (TSX:BCT) Business Description

Industry
Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko Director

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines